Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ORA-TESTRYL vs ACTIVELLA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Testosterone replacement therapy; binds to androgen receptors, promoting protein synthesis, muscle growth, and secondary sexual characteristic development.
Combination of estradiol, an estrogen, and norethindrone acetate, a progestin. Estrogens act by binding to nuclear estrogen receptors (ERα and ERβ), which then interact with estrogen response elements on DNA, leading to changes in gene expression that regulate growth, differentiation, and function of female reproductive tissues and other tissues. Norethindrone acetate is a progestin that induces secretory changes in the endometrium, reducing the risk of endometrial hyperplasia and carcinoma associated with unopposed estrogen therapy.
Primary hypogonadism,Hypogonadotropic hypogonadism,Off-label: testosterone deficiency symptoms
Treatment of moderate to severe vasomotor symptoms associated with menopause,Treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with menopause,Prevention of postmenopausal osteoporosis
Intramuscular injection: 50-100 mg every 2-4 weeks.
One tablet (1 mg estradiol + 0.5 mg norethindrone acetate) orally once daily, continuously.
Terminal half-life 2.5-3.5 hours; clinical context: requires multiple daily dosing to maintain steady-state levels
Estradiol has a terminal half-life of approximately 12–14 hours following transdermal administration. Norethindrone has a terminal half-life of approximately 8–10 hours. The combined product achieves steady-state within 3–5 days.
Metabolized in liver via CYP3A4 and CYP2C9 to androsterone, etiocholanolone, and 17-ketosteroids.
Estradiol is metabolized primarily in the liver via CYP3A4 and other CYPs, as well as by 17β-hydroxysteroid dehydrogenase and sulfotransferases. Norethindrone acetate is metabolized in the liver, primarily via reduction and conjugation, with CYP3A4 involved in some oxidative metabolism.
Renal (90% as glucuronide and sulfate conjugates, 10% unchanged); Biliary/fecal (10%)
Estradiol is primarily excreted in urine (∼50%) as glucuronide and sulfate conjugates, with ∼30% excreted in feces via biliary elimination. Norethindrone is excreted mainly in urine (∼60%) as metabolites, with ∼40% in feces.
97-99% bound to sex hormone-binding globulin (SHBG) and albumin
Estradiol is ∼98% bound to sex hormone-binding globulin (SHBG) and albumin. Norethindrone is ∼95–97% bound to SHBG and albumin.
0.5-1.0 L/kg; indicates extensive tissue distribution, including reproductive tissues
Estradiol has an apparent volume of distribution (Vd) of approximately 1.2 L/kg, indicating extensive distribution into tissues. Norethindrone has a Vd of approximately 3–5 L/kg, indicating wide distribution.
Oral: 3-6% (extensive first-pass metabolism); Buccal/sublingual: 20-40%
Transdermal estradiol has a bioavailability of approximately 10% relative to oral administration due to avoidance of first-pass metabolism. Oral norethindrone acetate has a bioavailability of approximately 50–60%.
No specific dose adjustment required for renal impairment; use with caution if GFR <30 m L/min.
No dose adjustment required for mild to moderate renal impairment. Not studied in severe renal impairment (Cr Cl <30 m L/min); use contraindicated.
Contraindicated in severe hepatic impairment (Child-Pugh class C). In moderate impairment (Child-Pugh class B), reduce dose by 50%.
Contraindicated in severe hepatic disease (Child-Pugh class C). For mild to moderate impairment (Child-Pugh A or B), use caution and monitor; no specific dose adjustment established.
Not recommended in pediatric patients for androgen replacement; safety and efficacy not established.
Not indicated for use in pediatric patients; safety and efficacy not established.
Use lowest effective dose (e.g., 50 mg IM every 4 weeks) due to increased risk of prostatic hypertrophy and cardiovascular events.
Start with the lowest effective dose; monitor for thromboembolic events and cognitive effects. No specific dose adjustment required, but consider age-related renal and hepatic decline.
Risk of blood clots, stroke, heart attack, and exacerbation of prostate cancer. Testosterone may be abused and cause serious health issues.
Estrogens increase the risk of endometrial cancer. There is an increased risk of cardiovascular events, breast cancer, and probable dementia with estrogen plus progestin therapy. Actively monitor for these events.
Cardiovascular risk, polycythemia, benign prostatic hyperplasia, sleep apnea, and edema. Monitor hematocrit, lipids, and prostate-specific antigen.
Cardiovascular disorders: Increased risks of stroke, myocardial infarction, and venous thromboembolism (VTE).,Malignancy: Increased risk of breast cancer, endometrial cancer, and ovarian cancer.,Probable dementia: Increased risk in women aged 65 years or older.,Gallbladder disease, hypertriglyceridemia, fluid retention, hypocalcemia, and hereditary angioedema.,Retinal thrombosis: Discontinue if sudden vision loss occurs.,Laboratory tests: May alter thyroid function tests, coagulation tests, and glucose tolerance.
Men with breast or prostate cancer, pregnant or breastfeeding women, hypersensitivity to testosterone, and patients with untreated sleep apnea.
Undiagnosed abnormal genital bleeding,Known, suspected, or history of breast cancer,Known or suspected estrogen-dependent neoplasia,Active or past history of venous thromboembolism (VTE) or arterial thromboembolism (ATE),Current or recent (within 1 year) VTE or ATE,Known thrombophilic disorders (e.g., protein C, S, or antithrombin deficiency; factor V Leiden mutation),Active or past history of arterial thromboembolic disease (e.g., stroke, MI),Known liver impairment or disease,Known or suspected pregnancy,Hypersensitivity to any component of the product
No significant food interactions. However, avoid grapefruit juice as it may alter metabolism. Avoid alcohol as it may exacerbate hepatotoxic effects.
Grapefruit juice may increase estrogen levels by inhibiting CYP3A4; avoid excessive consumption. High-fat meals can increase absorption of oral estrogens; take consistently with or without food to maintain steady levels.
Teratogenic risk profile: ORA-TESTRYL (testosterone undecanoate) is contraindicated in pregnancy. First trimester: virilization of female fetus; second and third trimesters: ongoing virilization, growth retardation. Class X. Transdermal testosterone has been associated with clitoromegaly, labial fusion, and urogenital sinus abnormalities in female fetuses.
Pregnancy Category X. Estrogen and progestin exposure during the first trimester is associated with congenital anomalies including cardiovascular and limb defects. Use during the second and third trimesters is contraindicated due to risk of fetal genital abnormalities and potential long-term neurodevelopmental effects. Avoid in pregnancy.
Excretion into breast milk is unknown. M/P ratio not established. Testosterone may suppress lactation and cause virilization of nursing infant. Discontinue breastfeeding or avoid drug.
Estradiol and norethindrone acetate are excreted into breast milk. Estradiol M/P ratio approximately 0.5; norethindrone M/P ratio approximately 0.4. May reduce milk production and alter composition. Use during breastfeeding is not recommended.
No dose adjustment applicable as drug is contraindicated in pregnancy. Pharmacokinetic changes (increased volume of distribution, altered protein binding) would necessitate dose reduction if used, but use is not recommended.
Not applicable; contraindicated in pregnancy.
ORA-TESTRYL (methyltestosterone buccal tablets) is an androgen replacement therapy for male hypogonadism. Buccal absorption avoids first-pass metabolism. Monitor liver function due to potential hepatotoxicity. Contraindicated in males with breast or prostate cancer. Avoid use in women due to virilization risks.
For patients with an intact uterus, estrogen must be combined with a progestogen (norethindrone acetate) to prevent endometrial hyperplasia. Initiate at the lowest effective dose for the shortest duration. Avoid in women with active thromboembolic disease, known or suspected breast cancer, or undiagnosed abnormal genital bleeding. Consider transdermal route if oral absorption is compromised or for migraine with aura.
Place tablet between cheek and gum and allow to dissolve; do not swallow or chew.,Do not eat, drink, or smoke while tablet is dissolving.,Use twice daily, once in morning and once in evening, at same times each day.,If you miss a dose, take it as soon as possible, but do not double up.,Report jaundice, dark urine, or abdominal pain immediately.,Regularly check liver function tests as directed by your doctor.,This medication may cause testicular shrinkage, gynecomastia, or worsening sleep apnea.,Not for use in women, especially those who are or may become pregnant.
Take this medication exactly as prescribed; do not skip doses or stop without consulting your doctor.,Report any unusual vaginal bleeding, breast lumps, or symptoms of blood clots (e.g., leg pain, chest pain, sudden shortness of breath, vision changes) immediately.,Smoking increases the risk of cardiovascular side effects, especially in women over 35; avoid smoking while on this therapy.,This medication does not protect against sexually transmitted infections or HIV.,Regular medical check-ups, including breast exams and mammograms, are essential during therapy.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ORA-TESTRYL vs ACTIVELLA, answered by our medical review team.
ORA-TESTRYL is a Androgen that works by Testosterone replacement therapy; binds to androgen receptors, promoting protein synthesis, muscle growth, and secondary sexual characteristic development.. ACTIVELLA is a Estrogen/Progestin Combination that works by Combination of estradiol, an estrogen, and norethindrone acetate, a progestin. Estrogens act by binding to nuclear estrogen receptors (ERα and ERβ), which then interact with estrogen response elements on DNA, leading to changes in gene expression that regulate growth, differentiation, and function of female reproductive tissues and other tissues. Norethindrone acetate is a progestin that induces secretory changes in the endometrium, reducing the risk of endometrial hyperplasia and carcinoma associated with unopposed estrogen therapy.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ORA-TESTRYL and ACTIVELLA depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ORA-TESTRYL is: Intramuscular injection: 50-100 mg every 2-4 weeks.. The standard adult dose of ACTIVELLA is: One tablet (1 mg estradiol + 0.5 mg norethindrone acetate) orally once daily, continuously.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ORA-TESTRYL and ACTIVELLA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ORA-TESTRYL is classified as Category C. Teratogenic risk profile: ORA-TESTRYL (testosterone undecanoate) is contraindicated in pregnancy. First trimester: virilization of female fetus; second and third trimesters: ongoin. ACTIVELLA is classified as Category C. Pregnancy Category X. Estrogen and progestin exposure during the first trimester is associated with congenital anomalies including cardiovascular and limb defects. Use during the s. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.